Jake Simson, Ph.D. has served as a member of our board of directors since March 2023. Since December 2020, Dr. Simson has served as a Partner of RA Capital Management, L.P., a life sciences investment advisor. Dr. Simson previously served as an associate, analyst and principal at RA Capital Management, L.P. from July 2013 to December 2020. Dr. Simson has served as a member of the board of directors of biotechnology and biopharmaceutical companies Tyra Biosciences, Inc. (Nasdaq: TYRA), Septerna, Inc. (Nasdaq: SEPT), and Janux Therapeutics, Inc. (Nasdaq: JANX) since January 2020, June 2023 and March 2021, respectively. Dr. Simson previously served on the board of directors of DICE Therapeutics, Inc. (Nasdaq: DICE), a biotechnology company, from December 2020 until it was acquired by Eli Lilly and Company in August 2023. Dr. Simson also serves on the boards of directors of various private companies. Dr. Simson received his Ph.D. in Biomedical Engineering from 13 Johns Hopkins University and his B.S. in Materials Science and Engineering from Massachusetts Institute of Technology. We believe Dr. Simson is qualified to serve on our board of directors due to his experience serving as a director for several private and public life science companies and his experience in the life sciences investment industry.